- Home
- HOLO vs NNVC Comparison
HOLO vs NNVC Comparison
Compare HOLO & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- NNVC
- Stock Information
- Founded
- HOLO 2018
- NNVC 2005
- Country
- HOLO China
- NNVC United States
- Employees
- HOLO N/A
- NNVC N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- NNVC Health Care
- Exchange
- HOLO Nasdaq
- NNVC Nasdaq
- Market Cap
- HOLO 24.9M
- NNVC 22.5M
- IPO Year
- HOLO N/A
- NNVC N/A
- Fundamental
- Price
- HOLO $5.12
- NNVC $1.68
- Analyst Decision
- HOLO
- NNVC
- Analyst Count
- HOLO 0
- NNVC 0
- Target Price
- HOLO N/A
- NNVC N/A
- AVG Volume (30 Days)
- HOLO 4.7M
- NNVC 334.4K
- Earning Date
- HOLO 01-01-0001
- NNVC 05-15-2025
- Dividend Yield
- HOLO N/A
- NNVC N/A
- EPS Growth
- HOLO N/A
- NNVC N/A
- EPS
- HOLO N/A
- NNVC N/A
- Revenue
- HOLO $39,771,750.00
- NNVC N/A
- Revenue This Year
- HOLO N/A
- NNVC N/A
- Revenue Next Year
- HOLO N/A
- NNVC N/A
- P/E Ratio
- HOLO N/A
- NNVC N/A
- Revenue Growth
- HOLO 42.62
- NNVC N/A
- 52 Week Low
- HOLO $4.16
- NNVC $0.94
- 52 Week High
- HOLO $608.00
- NNVC $2.50
- Technical
- Relative Strength Index (RSI)
- HOLO 44.22
- NNVC 60.67
- Support Level
- HOLO $5.07
- NNVC $1.54
- Resistance Level
- HOLO $5.59
- NNVC $1.79
- Average True Range (ATR)
- HOLO 0.85
- NNVC 0.10
- MACD
- HOLO 0.03
- NNVC 0.02
- Stochastic Oscillator
- HOLO 4.32
- NNVC 75.56
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.